Alkyl chain-modified cyclometalated iridium complexes as tunable anticancer and imaging agents

Area of Science:

• Organometallic Chemistry
• Medicinal Chemistry
• Materials Science

Background:

• Cyclometalated iridium complexes are explored for their photophysical and biological properties.
• Tuning ligand structure is key to modulating complex behavior.
• Alkyl chain length in ligands can impact steric and electronic properties.

Purpose of the Study:

• To synthesize and characterize novel mononuclear cyclometalated iridium complexes with varying alkyl chain lengths.
• To investigate the structure-activity relationship concerning anticancer properties and cellular imaging.
• To evaluate the potential of these complexes in anticancer research and diagnostics.

Main Methods:

• Synthesis of five iridium complexes ([1](PF6)-[5](PF6)) using imidazole-based ligands.
• Characterization using analytical techniques including single-crystal X-ray diffraction.
• In vitro anticancer activity assays (growth inhibition, IC50 values), cellular imaging (flow cytometry, fluorescence microscopy), and mechanistic studies (western blot).

Main Results:

• Complexes with shorter alkyl chains ([4]+, [5]+) exhibited significantly higher anticancer activity (IC50 < 0.5 μM) against MCF-7 cells compared to longer chains.
• Complexes [4]+ and [5]+ showed moderate selectivity for cancer cells over normal cells.
• Cellular accumulation correlated with anticancer activity; complex [1]+ demonstrated cell membrane imaging without toxicity.

Conclusions:

• Alkyl chain length is a critical determinant for both the anticancer efficacy and cellular imaging capabilities of these iridium complexes.
• Complexes [4]+ and [5]+ are promising candidates for anticancer drug development.
• Complex [1]+ shows potential for cell membrane imaging applications in anticancer research.